Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has been given a consensus recommendation of “Moderate Buy” by the seven analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $51.40.

A number of research firms have weighed in on COAG. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective for the company. Wedbush lifted their target price on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. HC Wainwright boosted their price target on Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Evercore assumed coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th.

Hemab Therapeutics Price Performance

COAG opened at $52.44 on Wednesday. The firm’s 50 day moving average price is $40.24. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $55.42. The stock has a market capitalization of $2.45 billion and a price-to-earnings ratio of -2.19.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, analysts forecast that Hemab Therapeutics will post -3.09 earnings per share for the current year.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was acquired at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the purchase, the insider owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.